Faculty of Pharmacy in cooperation with Department for Nuclear Medicine, University Medical Centre Ljubljana and Federal Swiss university ETH Zurich organized two-weeks Postgraduate European Radiopharmacy Course (PERC) in 2011 and 2013. The courses were organized at Faculty of Pharmacy in Ljubljana. All together 29 and 30 students from Austria, Bosnia and Herzegovina, Danmark, Finland, France, Greece, Italy, India, Canada, Hungary, Germany, The Netherlands, Norway, Poland, Portugal, Russia, Saudi Arabia, Serbia, Spain, Switzerland, Thailand, Turkey and UK attended the courses. PERC is part of the European scheme of postgraduate specialisation cerificate in radiopharmacy as one of the three theoretical blocks. The Eduaction was established by Radiopharmacy Committee, European Association of Nuclear Medicine (EANM). Pharmacists, Chemists and biochemists with (minimal) Masters Degree can attend the education in English language. Theoretical blocks are organized in differeent european countries. Block 1, organized in Ljubljana is the only one in Europe (http://www.eanm.org/education_esnm/additional_activities/radiopharmacy_course.php?navId=296&PHPSESSID=0l050s9v21cd9mm54hiucs55e4) Block 1 Postgraduate European Radiopharmaceutical Chemistry/Radiopharmacy Course (PERC) in Ljubljana is an intensive two-week theoretical course with practical aspects. It introduces fundamentals in drug development, formulation, evaluation, including biopharmaceutical aspects and European legislation. Special emphasis is laid on good practices and quality assurance of parenterals and clinical trials.
B.01 Organiser of a scientific meeting
COBISS.SI-ID: 3358321Public awareness of the principles of the use of biological targeted drugs that act directed at a type of cancer cells is of paramount importance, as this contributes to the understanding of the use in targeted patient population. Hence, it contributes to appreciation of the public and patients towards often hard-to–accept therapeutic decisions of physicians and pharmacist. Modern pharmacotherapy requires the active participation of patients, who need to understand the mode of drug action, the basis for genetic diagnostic testing and consequent choice of drugs. Communication with the public strengthen individual awareness about the specificities of disease and use of targeted drugs. The project member have contributed to the development of an imaging agent for detection of CD-20 positive lymphoma. Developed methodology has enabled a production of stable photoreduced rituximab which can be stored for longer period of time allowing clinical usage and immediate radiolabelling with (99mTc) pertechnetate, prior to application into patient. We have confirmed that radiopharmaceutical is suitable for imaging agent for early detection, staging, subsequent remission assessment and monitoring for metastatic spread and tumour recurrence of non Hodkin Lymphoma.
F.25 Development of new organisational structures and managerial solutions
COBISS.SI-ID: 3220081Dr. Jure Fettich - Executive Committee member, treasurer
D.03 Membership in foreign/international boards/committees
Dr. Petra Kolenc Peitl, Radiopharmacy Committee Member, secretary.
D.03 Membership in foreign/international boards/committees
Dr. Jure Fettich - editorial board member of: Nuclear Medicine Communications, World Journal of Nuclear Medicine, European Journal of Nuclear Medicine& Molecular Imaging. Dr. Luka Ležaić -editorial board member of Journal of Molecular Imaging & Dynamics
C.04 Editorial board of an international magazine